Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Aberdeen Group plc

Aberdeen Group plc increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 94.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 973,656 shares of the biopharmaceutical company’s stock after buying an additional 472,600 shares during the period. Aberdeen Group plc owned about 1.01% of Ultragenyx Pharmaceutical worth $29,288,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RARE. Assetmark Inc. increased its position in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Rhumbline Advisers grew its stake in Ultragenyx Pharmaceutical by 2.0% during the 3rd quarter. Rhumbline Advisers now owns 105,731 shares of the biopharmaceutical company’s stock valued at $3,180,000 after purchasing an additional 2,105 shares in the last quarter. Profund Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 99.6% during the 3rd quarter. Profund Advisors LLC now owns 32,264 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 16,098 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Ultragenyx Pharmaceutical by 25.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 8,142 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 1,628 shares in the last quarter. Finally, Candriam S.C.A. boosted its stake in shares of Ultragenyx Pharmaceutical by 43.4% during the 3rd quarter. Candriam S.C.A. now owns 754,714 shares of the biopharmaceutical company’s stock valued at $22,702,000 after buying an additional 228,447 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on RARE while lowering its price target from $60 to $50, signaling continued analyst conviction in the company’s upside despite the cut. HC Wainwright lowers PT but maintains Buy
• Positive Sentiment: Coverage pieces highlight Ultragenyx’s strong rare-disease pipeline and sizable upside potential, reinforcing longer-term bullish views that may attract investors focused on pipeline value. Pipeline-driven bullish coverage
• Neutral Sentiment: Wedbush reaffirmed a Neutral rating with a $25 price target, suggesting some analysts see limited near-term catalysts while others remain constructive — this creates mixed signals for traders. Wedbush reaffirms Neutral
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors to join a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering purchases from Aug 3, 2023 to Dec 26, 2025; the lead-plaintiff deadline is April 6, 2026 — this legal overhang can pressure the stock and increase perceived risk. KSF class action notice Rosen Law Firm notice Schall Law Firm notice Robbins Geller notice Kessler Topaz complaint Faruqi & Faruqi reminder
• Negative Sentiment: Ultragenyx announced a roughly 10% workforce reduction as it targets profitability in 2027; while cost cuts could improve longer-term margins, layoffs and execution risk typically weigh on near-term sentiment. Workforce reduction announcement

Ultragenyx Pharmaceutical Trading Down 1.7%

Shares of Ultragenyx Pharmaceutical stock opened at $20.18 on Wednesday. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -3.46 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.41 and a twelve month high of $45.00. The business’s 50 day simple moving average is $26.27 and its 200-day simple moving average is $29.66.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The company had revenue of $207.00 million for the quarter, compared to the consensus estimate of $199.60 million. During the same quarter in the previous year, the company earned ($1.39) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RARE. Jefferies Financial Group cut their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. HC Wainwright reduced their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Wedbush reiterated a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Finally, Wells Fargo & Company cut their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.18.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the transaction, the chief financial officer owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.